Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency
Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals.
Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1
While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sharply when it comes to operational readiness. Nearly eight in 10 GPs (79%) anticipate growth in the sector over the next three years, with more than half (51%) expecting a significant acceleration. LPs, however, are increasingly cautious—40% reported turning down multiple fund or investment opportunities last year due to operational concerns such as inconsistent reporting standards and unclear risk frameworks.
“The global expansion of private credit is undeniable, but the operational complexity it brings must not be underestimated,” said Bas Coenen, CSC’s head of Fund Solutions, Europe. “Operating across multiple jurisdictions introduces a maze of reporting requirements, investor expectations, and compliance standards. Even managing a handful of markets can prove challenging. The message from investors is clear: confidence in cross-border strategies hinges on transparency, regulatory alignment, and flawless execution.”
GPs recognize the operational challenges that come with cross-border expansion—particularly around anti-money laundering (AML) regulations, multijurisdictional reporting, and enforcing covenants across diverse legal systems. Transparency and reporting demands from LPs now rank among managers’ top concerns, second only to the complexity of deal structuring.
At the same time, LPs are shifting their priorities toward more granular and consistent data on loan performance and borrower credit quality. These metrics now rank just behind loan-level returns and borrower payment trends, while broader measures such as liquidity and portfolio risk visibility are being assessed through this more granular data.
To meet rising expectations and scale effectively, many GPs are investing in technology upgrades and partnering with specialist service providers. Currently, 82% rely on third-party loan agents, with 66% doing so regularly over the past year, and 88% expect usage to increase. LPs strongly endorse this shift: 92% believe GPs who outsource to trusted specialists are better equipped to deliver enhanced reporting and risk transparency, especially in complex cross-border environments.
“Private credit is inherently a hands-on asset class - far more operationally intensive than equity investing,” said CSC’s David Kim, managing director, North America. “LPs know the data is available, and they’re demanding more of it—greater transparency, consistency, and detail. That’s putting real pressure on managers to elevate their reporting capabilities and strengthen operational frameworks.”
He added: “Many are now seeking partners who can support them across the full investment life cycle, from loan agency and fund administration to SPV management. CSC is among the few with the scale, expertise, and infrastructure to deliver truly end-to-end solutions.”
To receive a copy of CSC’s Private Credit 2025: Global Strategies for a $1.5 Trillion Market, please download it at cscglobal.com/service/campaigns/private-credit-2025.
1CSC, in partnership with PureProfile, surveyed 500 private capital professionals globally, comprising 300 GPs and 200 LPs across North America, Europe (including the U.K.), and Asia-Pacific. Respondents held senior positions within fund management, investment, and risk functions across asset management, pension funds, insurance, and wealth management sectors.
About CSC
CSC is the leading provider of business administration and compliance solutions, offering industry-leading expertise and unmatched global reach to alternative fund managers and capital markets participants. Leveraging deep institutional experience and a tailored approach, CSC delivers a comprehensive suite of fund administration, trust, agency, and compliance services to support a wide range of private and public market transactions, complex fund strategies, and scalable operations.
As the trusted partner of choice for more than 70% of the PEI 300 and 90% of the Fortune 500®, CSC helps clients navigate operational and transactional complexities across more than 140 jurisdictions and various asset classes. With extensive worldwide capabilities, our expert teams provide solutions tailored to each client’s needs. Privately held and professionally managed since 1899, we combine global reach, local expertise, and innovative solutions to help our clients succeed.
We are the business behind business®. Learn more at cscglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251204982051/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Launches Breakthrough Index Integrating Public Markets and Private Equity4.12.2025 15:00:00 CET | Press release
Innovative index is designed to provide a broad and daily view of the global equity opportunity MSCI Inc. (NYSE: MSCI) launched the MSCI All Country Public + Private Equity Index,an innovative daily index that combines public markets and a broad private equity view within a single, coherent framework. The launch marks a major shift in how investors can assess total equity exposures and measure performance across their portfolio. With private markets increasingly integrated into investment portfolios, private equity is becoming a core component of total portfolio allocation, contributing to diversification, long-term return potential and exposure to segments of the economy not captured by public markets. Reflecting the evolving structure of investor portfolios, this index sets a new standard for tracking global equity performance across public and private markets. The index combines the flagship MSCI ACWI IMI, which represents the performance of the full opportunity set of publicly list
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health4.12.2025 15:00:00 CET | Press release
Funding from Baszucki Group fuels program for healthcare professionals to learn by doing. Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. The program, titled “LIVE IT~LAUNCH IT: Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health in Your Patients For Health Care Workers” is led by Deanna Kelly, PharmD, BCPP, the Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research and Director of the Maryland Psychiatric Research Center at the University of Maryland School of Medicine. This initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and resear
I-care Group Continues Global Expansion with a European Training Arm4.12.2025 15:00:00 CET | Press release
Technical Associates of Europe builds on 60+ years of training excellence I-care Group, the global leader in predictive maintenance and reliability solutions, announces the launch of Technical Associates of Europe (TAE), a new independent and certifying training organization headquartered in Mons, Belgium. This strategic initiative strengthens I-care’s global development and extends its professional training offerings in maintenance, reliability, lubrication and predictive-maintenance technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204628319/en/ Building on the heritage of Technical Associates of Charlotte (TAC) — a U.S. training organization founded in 1961 and acquired by I-care Group in 2023 —Technical Associates of Europe represents a major expansion of I-care’s training ecosystem. “Technical Associates of Europe marks an important milestone in I-care’s journey,” said Fabrice Brion, CEO of I-care Group. “
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom